Return to homepagePandemic Pact

A Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection [ICE study]

Grant number: CVD/2020/000990

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    SERB India

  • Principal Investigator

    Dr. Biju George

  • Research Location

    India

  • Lead Research Institution

    Christian Medical College

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Other

  • Occupations of Interest

    Unspecified

Abstract

Drug repurposing against key COVID-19 targets

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial.